[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JO3188B1 - بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل - Google Patents

بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل

Info

Publication number
JO3188B1
JO3188B1 JOP/2011/0075A JOP20110075A JO3188B1 JO 3188 B1 JO3188 B1 JO 3188B1 JO P20110075 A JOP20110075 A JO P20110075A JO 3188 B1 JO3188 B1 JO 3188B1
Authority
JO
Jordan
Prior art keywords
antigen binding
binding proteins
component
serum amyloid
proteins specific
Prior art date
Application number
JOP/2011/0075A
Other languages
English (en)
Inventor
Peter Lewis Alan
Kaur Bhinder Tejinder
Karen Ford Susannah
Germaschewski Volker
Brian Pepys Mark
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3188(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of JO3188B1 publication Critical patent/JO3188B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات ربط مولد الضد، مثل الأجسام المضادة، التي ترتبط بمكون P نشواني مصلي (SAP)، وبولي نوكليوتيدات تشفر بروتينات ربط مولد الضد المذكورة، وتركيبات صيدلانية تشتمل على بروتينات ربط مولد الضد المذكورة وطرق تصنيعها. يتعلق الاختراع الحالي أيضاً استخدام بروتينات ربط مولد الضد المذكورة في علاج أو الوقاية من الأمراض المصاحبة لترسيب المواد النشوانية بما في ذلك الداء النشواني الذي يعم الجسم كله، والداء النشواني الموضعي، ومرض الزهايمر ومرض السكري النوع 2.
JOP/2011/0075A 2010-03-03 2011-03-01 بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل JO3188B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
JO3188B1 true JO3188B1 (ar) 2018-03-08

Family

ID=43881068

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0075A JO3188B1 (ar) 2010-03-03 2011-03-01 بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل

Country Status (39)

Country Link
EP (2) EP3025729B1 (ar)
JP (2) JP5922592B2 (ar)
KR (1) KR101817265B1 (ar)
CN (1) CN102858371B (ar)
AR (1) AR080432A1 (ar)
AU (1) AU2011223048C1 (ar)
BR (1) BR112012021926A2 (ar)
CA (1) CA2789557A1 (ar)
CL (1) CL2012002418A1 (ar)
CO (1) CO6602134A2 (ar)
CR (1) CR20120491A (ar)
CY (2) CY1118046T1 (ar)
DK (2) DK2542261T3 (ar)
DO (1) DOP2012000232A (ar)
EA (1) EA026375B1 (ar)
ES (2) ES2593454T3 (ar)
HK (2) HK1173959A1 (ar)
HR (2) HRP20161096T1 (ar)
HU (1) HUE028960T2 (ar)
IL (2) IL221418A (ar)
JO (1) JO3188B1 (ar)
LT (2) LT3025729T (ar)
MA (1) MA34135B1 (ar)
ME (1) ME02491B (ar)
MX (1) MX340350B (ar)
MY (1) MY159255A (ar)
NZ (1) NZ601763A (ar)
PE (1) PE20130040A1 (ar)
PL (2) PL2542261T3 (ar)
PT (2) PT3025729T (ar)
RS (2) RS55133B1 (ar)
SG (2) SG10201500382SA (ar)
SI (2) SI2542261T1 (ar)
SM (1) SMT201600337B (ar)
TW (1) TWI558409B (ar)
UA (1) UA108227C2 (ar)
UY (1) UY33258A (ar)
WO (1) WO2011107480A1 (ar)
ZA (1) ZA201206529B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6251477B2 (ja) * 2009-12-02 2017-12-20 イマジナブ・インコーポレーテッド ヒト前立腺特異的膜抗原（ｐｓｍａ）をターゲッティングするｊ５９１ミニボディおよびｃｙｓダイアボディならびにこれらを使用するための方法
AU2013364043B2 (en) * 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
KR20000070865A (ko) 1997-02-07 2000-11-25 폴락 돈나 엘. 합성 ＨＩＶ ｇａｇ 유전자
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
PL217751B1 (pl) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004099173A1 (en) 2003-05-12 2004-11-18 Theracarb Inc. Multivalent inhibitors of serum amyloid p component
EP1776385A1 (en) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use

Also Published As

Publication number Publication date
IL251031A (en) 2017-11-30
LT2542261T (lt) 2016-09-26
NZ601763A (en) 2014-08-29
EA026375B1 (ru) 2017-04-28
CN102858371B (zh) 2017-03-01
RS55133B1 (sr) 2016-12-30
SMT201600337B (it) 2016-11-10
KR101817265B1 (ko) 2018-01-10
KR20130027483A (ko) 2013-03-15
ZA201206529B (en) 2018-12-19
IL221418A (en) 2017-03-30
EP2542261B1 (en) 2016-07-06
AU2011223048A1 (en) 2012-10-04
PL2542261T3 (pl) 2016-12-30
TW201143789A (en) 2011-12-16
UA108227C2 (xx) 2015-04-10
EP3025729A1 (en) 2016-06-01
IL251031A0 (en) 2017-04-30
JP2013521252A (ja) 2013-06-10
EA201290671A1 (ru) 2013-05-30
SI2542261T1 (sl) 2016-11-30
CY1118046T1 (el) 2017-05-17
HK1173959A1 (zh) 2013-05-31
SI3025729T1 (sl) 2018-11-30
CA2789557A1 (en) 2011-09-09
SG10201500382SA (en) 2015-03-30
EP3025729B1 (en) 2018-09-12
CN102858371A (zh) 2013-01-02
LT3025729T (lt) 2018-12-10
SG183316A1 (en) 2012-09-27
PL3025729T3 (pl) 2019-02-28
HUE028960T2 (en) 2017-01-30
PE20130040A1 (es) 2013-02-09
ES2699078T3 (es) 2019-02-07
AR080432A1 (es) 2012-04-11
RS57708B1 (sr) 2018-12-31
MX340350B (es) 2016-07-06
TWI558409B (zh) 2016-11-21
WO2011107480A1 (en) 2011-09-09
PT3025729T (pt) 2018-11-30
DOP2012000232A (es) 2013-01-15
AU2011223048C1 (en) 2018-06-21
ES2593454T3 (es) 2016-12-09
CR20120491A (es) 2013-02-20
DK3025729T3 (en) 2018-11-26
JP5922592B2 (ja) 2016-05-24
ME02491B (me) 2017-02-20
IL221418A0 (en) 2012-10-31
DK2542261T3 (en) 2016-09-19
HRP20161096T1 (hr) 2016-11-04
EP2542261A1 (en) 2013-01-09
CO6602134A2 (es) 2013-01-18
HRP20181666T1 (hr) 2018-12-14
MA34135B1 (fr) 2013-04-03
CL2012002418A1 (es) 2013-03-08
CY1120803T1 (el) 2019-12-11
BR112012021926A2 (pt) 2020-08-25
MY159255A (en) 2016-12-30
MX2012010129A (es) 2012-09-12
JP2016154535A (ja) 2016-09-01
UY33258A (es) 2011-09-30
JP6236478B2 (ja) 2017-11-22
PT2542261T (pt) 2016-09-27
AU2011223048B2 (en) 2013-12-19
HK1223292A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
AU2018256498A1 (en) Antibodies to amyloid beta
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
MX356800B (es) Anticuerpo tau humanizado.
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201190018A1 (ru) Миостатинсвязывающие белки
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
MX357193B (es) Moleculas de union anti-alfa sinucleina.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
WO2009048537A3 (en) Humanized antibody
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
TN2011000150A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
UA97414C2 (ru) Выделенное человеческое антитело, связывающееся с gm-csf